Ovid Therapeutics, Inc.
Industry
- Biotechnology
- Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
Latest on Ovid Therapeutics, Inc.
Meg Alexander, president and chief operating officer of Ovid Therapeutics, brings extensive industry experience to her role at the New York-based biotech, a company focused on developing medicines for
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
A letter to US Senate Health, Education, Labor and Pensions (HELP) committee chairman Bill Cassidy, R-LA, from more than 200 biotech leaders, investors and patient advocates cites cases of disruptions
Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list